Clinical Trial Update: Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating chemotherapy with or without dalteparin for metastatic pancreatic cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• FRAGMIN (DALTEPARIN SODIUM)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Chemotherapeutic Agent Toxicity, Pancreatic Cancer | Phase 3 | Status: TERMINATED